Solid Dosage Products: Tracking the Market

What are key moves and trends by CDMOs/CMOs and suppliers in the oral solid-dosage market? A look at key market and technology developments.

Solid growth
The global oral solid dosage (OSD) contract manufacturing market is expected to reach $54.7 billion by 2030 and expand at a compound annual growth rate (CAGR) of 5.97% from 2024 to 2030, according to a recent analysis by Grand View Research. Increasing complexity of new drug molecules, R&D investments by large CMOs & CDMOs and rising demand for novel therapies are key factors driving market growth.

The tablets segment dominated the market with a revenue share of 32.7% in 2023. Tablets are the most common and preferred OSD form due to their cost-effectiveness, high compactness, easy manufacturing, and convenience of self-administration. Increased demand for bilayer tablets and investments by firms to expand formulation and controlled-release tablet manufacturing are predicted to drive market growth

The controlled-release segment accounted for the largest share with 52.2% in 2023. This growth is attributed to advancements in oral controlled-release delivery systems, including dome tablets, dual drug tablets, intestinal patches, polymer nanosystems, and bioinspired delivery methods, such as exosomes for precise drug delivery. Thus, high demand for controlled-release dosage forms is anticipated to boost segmental revenue growth in the near future

Based on end-use, the large-size companies segment accounted for the largest share in 2023 with a 54.8% share, according to Grand View Research The solid dose manufacturing market is increasingly defined by collaboration, flexibility, and high adaptability. More pharma developers design drugs from the start, intending to outsource them to large CMOs, thereby accelerating market growth. Furthermore, CMOs specializing in oral solid dosage can provide several benefits to large pharmaceutical companies, leading to their increased adoption

Asia-Pacific led the global market in 2023 on a geographic growth basis and is projected to see the fastest CAGR of 6.3% during the forecast years, led by growth in China and India. Expanding manufacturing capabilities among Asian countries such as Singapore, India, and South Korea will also contribute to growth in the region.

Recent Feature Articles

AI: The Marriage of High Tech & Big Pharma

By
Novo Nordisk is the latest pharmaceutical major to partner directly with a high-tech giant to advance AI in their operations, including for drug development, manufacturing, and the supply chain. A roundup of the latest partnerships and projects.

Mastering the Supply Chain, Digitalization & Global Shifts

By
An upcoming DCAT conference, The DCAT Global Summit 2026: The Future of Bio/Pharma: Mastering the Supply Chain, Digitalization & Global Shifts, June 10-11, in Sitges, Barcelona, Spain, will provide executive perspectives on AI and digital transformation across the bio/pharmaceutical value chain.

CEOs, Senior Executives Highlight Expansions at the DCAT Member Company Announcement Forum

By
CEOs and senior executives from DCAT Member Companies highlighted their companies’ major news at the DCAT Member Company Announcement Forum at DCAT Week.

DCAT Value Chain Insights Bonus Coverage: From DCAT Week 2026 Member Company News Roundup 

By
What other DCAT Member Companies are making news from DCAT Week? A roundup of the latest developments from suppliers and CDMOs/CMOs.